IN2014DN07194A - - Google Patents
Info
- Publication number
- IN2014DN07194A IN2014DN07194A IN7194DEN2014A IN2014DN07194A IN 2014DN07194 A IN2014DN07194 A IN 2014DN07194A IN 7194DEN2014 A IN7194DEN2014 A IN 7194DEN2014A IN 2014DN07194 A IN2014DN07194 A IN 2014DN07194A
- Authority
- IN
- India
- Prior art keywords
- bacteria
- resistant bacteria
- fulvic acid
- antibiotics
- drug resistant
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 abstract 5
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 abstract 2
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 abstract 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 2
- 229940088710 antibiotic agent Drugs 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940095100 fulvic acid Drugs 0.000 abstract 2
- 239000002509 fulvic acid Substances 0.000 abstract 2
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 241000588747 Klebsiella pneumoniae Species 0.000 abstract 1
- 101000740455 Klebsiella pneumoniae Metallo-beta-lactamase type 2 Proteins 0.000 abstract 1
- 108010040201 Polymyxins Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 108010068385 carbapenemase Proteins 0.000 abstract 1
- 229940041011 carbapenems Drugs 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Fulvic acid as the active ingredient is used in the treatment or inhibition of multi-drug resistant bacteria, in particular NDM-1 bacteria producing carbapenemase or extended-spectrum plactamase (ESBL) resistant bacteria. The multi-drug resistant bacteria may be gram negative bacteria including, but not limited to, Klebsiella pneumoniae or Escherichia coli. The fulvic acid can be provided in combination with one or more antibiotics from the class of carbapenems or polymyxin antibiotics.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA201201683 | 2012-03-07 | ||
| PCT/IB2013/051772 WO2013132444A1 (en) | 2012-03-07 | 2013-03-06 | Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN07194A true IN2014DN07194A (en) | 2015-04-24 |
Family
ID=48142838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN7194DEN2014 IN2014DN07194A (en) | 2012-03-07 | 2013-03-06 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9265744B2 (en) |
| EP (1) | EP2822551B1 (en) |
| KR (1) | KR20140135813A (en) |
| CN (1) | CN104203227A (en) |
| IN (1) | IN2014DN07194A (en) |
| MY (1) | MY170829A (en) |
| RU (1) | RU2640928C2 (en) |
| WO (1) | WO2013132444A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10201518B2 (en) | 2016-09-28 | 2019-02-12 | The University Of Hong Kong | Bismuth(III) compounds and methods thereof |
| CN109706195B (en) * | 2018-12-27 | 2022-04-08 | 齐齐哈尔龙江阜丰生物科技有限公司 | Production process of granular threonine |
| CN111616358A (en) * | 2020-06-20 | 2020-09-04 | 田劭军 | Composition for improving immunity and application thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ225271A (en) | 1987-07-08 | 1991-02-26 | Nat Energy Council | Oxidising coal using a gaseous oxidant |
| DE3903773A1 (en) | 1988-02-11 | 1989-09-14 | Nat Energy Council | A MIXTURE WITH BACTERIOZIDER OR BACTERIOSTATIC ACTIVITY |
| US5204368A (en) | 1990-05-25 | 1993-04-20 | National Energy Council | Bacteriostatic and bacteriocidal method using fulvic acid derivatives |
| DE69939722D1 (en) | 1998-10-08 | 2008-11-20 | Pfeinsmith Ltd | Fulvic acid and its use in the treatment of inflammation |
| EP1895898B1 (en) | 2005-06-29 | 2011-02-16 | Compumedics Limited | Sensor assembly with conductive bridge |
| US8114910B2 (en) * | 2006-05-02 | 2012-02-14 | Pfeinsmith S.A. (Pty) Ltd. | Acidic composition |
| US8445452B2 (en) * | 2008-06-05 | 2013-05-21 | Pfeinsmith Ltd. | Fulvic acid and antibiotic combination |
-
2013
- 2013-03-06 IN IN7194DEN2014 patent/IN2014DN07194A/en unknown
- 2013-03-06 MY MYPI2014702359A patent/MY170829A/en unknown
- 2013-03-06 RU RU2014140227A patent/RU2640928C2/en active
- 2013-03-06 CN CN201380012421.XA patent/CN104203227A/en active Pending
- 2013-03-06 KR KR1020147028255A patent/KR20140135813A/en not_active Application Discontinuation
- 2013-03-06 US US14/383,429 patent/US9265744B2/en active Active
- 2013-03-06 WO PCT/IB2013/051772 patent/WO2013132444A1/en active Application Filing
- 2013-03-06 EP EP13717565.9A patent/EP2822551B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140135813A (en) | 2014-11-26 |
| US9265744B2 (en) | 2016-02-23 |
| US20150031767A1 (en) | 2015-01-29 |
| EP2822551A1 (en) | 2015-01-14 |
| RU2640928C2 (en) | 2018-01-12 |
| WO2013132444A1 (en) | 2013-09-12 |
| RU2014140227A (en) | 2016-04-27 |
| MY170829A (en) | 2019-09-05 |
| EP2822551B1 (en) | 2016-12-21 |
| CN104203227A (en) | 2014-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013184755A3 (en) | Seca inhibitors and methods of making and using thereof | |
| PH12016501512B1 (en) | Treatment for resistant acne | |
| MX2019009132A (en) | Synergistic bacterial compositions and methods of production and use thereof. | |
| MX2016002765A (en) | Use of a composition comprising microorganisms to increase the intestinal production of butyric acid, folic acid or niacin and/or decrease the intestinal production of succinic acid. | |
| IN2015DN01198A (en) | ||
| MX2019012877A (en) | Biofilm prevention, disruption and treatment with bacteriophage lysin. | |
| EP4233545A3 (en) | Synergistic bacterial compositions and methods of production and use thereof | |
| TN2013000310A1 (en) | Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections | |
| WO2017017631A3 (en) | Antibacterial therapeutics and prophylactics | |
| WO2014007951A3 (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| MX353705B (en) | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo. | |
| MX352760B (en) | Methods for treating intrapulmonary infections. | |
| MX363678B (en) | Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections. | |
| SG10201900541QA (en) | Derivatives of xanthone compounds | |
| BR112014002940A2 (en) | use and agrochemical composition of carboxylic acid dibutylamides | |
| IN2014DN07194A (en) | ||
| WO2013162772A3 (en) | Perforin 2 defense against invasive and multidrug resistant pathogens | |
| AU2012335397A8 (en) | Novel bacteriophages | |
| UA118554C2 (en) | Synergistic antimicrobial combinations containing chlorine dioxide and organic acid useful for controlling microorganisms in industrial processes | |
| NZ713440A (en) | Nsaid administration and related compositions, methods and systems. | |
| MY180113A (en) | Use of patchouli extract in the preparation of compositions with an anti-microorganism effect | |
| IN2015DN02513A (en) | ||
| Opoku | AmpC Beta-Lactamase Production Among Pseudomonas Aeruginosa and proteus Mirabilis Clinical Isolates at the Komfo Anakye Teaching hospital in Kumasi, Ghana | |
| MX2016005869A (en) | Crystalline beta-lactamase inhibitor. | |
| RU2015133469A (en) | Antimicrobial combination against carbapenem-resistant gram-negative microorganisms producing metallo-β-lactamase |